Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $53 from $39 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report was uneventful as pipeline progress remains on track. Top-line Ph3 data in the lead mLM indication will come in 1Q26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
- High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
- Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
- Palvella Therapeutics Reports 2024 Financial Results and Updates
- Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)